The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

NSC-612049     9-[5-(hydroxymethyl)oxolan-2- yl]-3H-purin...

Synonyms: AG-J-03151, SureCN4301211, SureCN5021456, ACMC-209oa4, D7039_SIGMA, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC612049


Psychiatry related information on NSC612049

  • Many of the dideoxynucleosides effective systemically in the treatment of HIV infections, such as 2',3'-dideoxyinosine (ddI), exhibit limited penetration into the CNS and limited or variable effectiveness in reversing the symptoms of AIDS dementia [6].

High impact information on NSC612049


Chemical compound and disease context of NSC612049


Biological context of NSC612049


Anatomical context of NSC612049


Associations of NSC612049 with other chemical compounds


Gene context of NSC612049


Analytical, diagnostic and therapeutic context of NSC612049


  1. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. Butler, K.M., Husson, R.N., Balis, F.M., Brouwers, P., Eddy, J., el-Amin, D., Gress, J., Hawkins, M., Jarosinski, P., Moss, H. N. Engl. J. Med. (1991) [Pubmed]
  2. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. Lambert, J.S., Seidlin, M., Reichman, R.C., Plank, C.S., Laverty, M., Morse, G.D., Knupp, C., McLaren, C., Pettinelli, C., Valentine, F.T. N. Engl. J. Med. (1990) [Pubmed]
  3. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Yarchoan, R., Mitsuya, H., Thomas, R.V., Pluda, J.M., Hartman, N.R., Perno, C.F., Marczyk, K.S., Allain, J.P., Johns, D.G., Broder, S. Science (1989) [Pubmed]
  4. Fatal case of 2',3'-dideoxyinosine-associated pancreatitis. Bouvet, E., Casalino, E., Prevost, M.H., Vachon, F. Lancet (1990) [Pubmed]
  5. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Lai, K.K., Gang, D.L., Zawacki, J.K., Cooley, T.P. Ann. Intern. Med. (1991) [Pubmed]
  6. Central nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs. Morgan, M.E., Chi, S.C., Murakami, K., Mitsuya, H., Anderson, B.D. Antimicrob. Agents Chemother. (1992) [Pubmed]
  7. 3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Ren, J., Esnouf, R.M., Hopkins, A.L., Jones, E.Y., Kirby, I., Keeling, J., Ross, C.K., Larder, B.A., Stuart, D.I., Stammers, D.K. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  8. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes. Malley, S.D., Grange, J.M., Hamedi-Sangsari, F., Vila, J.R. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  9. Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Japour, A.J., Chatis, P.A., Eigenrauch, H.A., Crumpacker, C.S. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  10. Didanosine once daily: an overview. Youle, M. Antivir. Ther. (Lond.) (1998) [Pubmed]
  11. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Perno, C.F., Cooney, D.A., Gao, W.Y., Hao, Z., Johns, D.G., Foli, A., Hartman, N.R., Caliò, R., Broder, S., Yarchoan, R. Blood (1992) [Pubmed]
  12. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. St Clair, M.H., Martin, J.L., Tudor-Williams, G., Bach, M.C., Vavro, C.L., King, D.M., Kellam, P., Kemp, S.D., Larder, B.A. Science (1991) [Pubmed]
  13. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Schacter, L.P., Rozencweig, M., Beltangady, M., Allan, J.D., Canetta, R., Cooley, T.P., Dolin, R., Kelley, S., Lambert, J., Liebman, H.A. Blood (1992) [Pubmed]
  14. Targeted therapy of human immunodeficiency virus-related disease. Mitsuya, H., Yarchoan, R., Kageyama, S., Broder, S. FASEB J. (1991) [Pubmed]
  15. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. Haertle, T., Carrera, C.J., Wasson, D.B., Sowers, L.C., Richman, D.D., Carson, D.A. J. Biol. Chem. (1988) [Pubmed]
  16. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group. Jablonowski, H., Arasteh, K., Staszewski, S., Ruf, B., Stellbrink, H.J., Schrappe, M., Stoehr, A., Haase, W., Schomaker, U., von Eisenhart Rothe, B. AIDS (1995) [Pubmed]
  17. Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyinosine. Harvie, P., Désormeaux, A., Gagné, N., Tremblay, M., Poulin, L., Beauchamp, D., Bergeron, M.G. AIDS (1995) [Pubmed]
  18. 2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine. Masood, R., Ahluwalia, G.S., Cooney, D.A., Fridland, A., Marquez, V.E., Driscoll, J.S., Hao, Z., Mitsuya, H., Perno, C.F., Broder, S. Mol. Pharmacol. (1990) [Pubmed]
  19. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Johnson, M.A., Fridland, A. Mol. Pharmacol. (1989) [Pubmed]
  20. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. Larder, B.A., Kohli, A., Bloor, S., Kemp, S.D., Harrigan, P.R., Schooley, R.T., Lange, J.M., Pennington, K.N., St Clair, M.H. J. Virol. (1996) [Pubmed]
  21. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. Balis, F.M., Pizzo, P.A., Butler, K.M., Hawkins, M.E., Brouwers, P., Husson, R.N., Jacobsen, F., Blaney, S.M., Gress, J., Jarosinski, P. J. Infect. Dis. (1992) [Pubmed]
  22. In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. Hayashi, S., Fine, R.L., Chou, T.C., Currens, M.J., Broder, S., Mitsuya, H. Antimicrob. Agents Chemother. (1990) [Pubmed]
  23. Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. Takasawa, K., Terasaki, T., Suzuki, H., Ooie, T., Sugiyama, Y. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  24. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Balzarini, J., Karlsson, A., Pérez-Pérez, M.J., Camarasa, M.J., De Clercq, E. Virology (1993) [Pubmed]
  25. Differential kinetics of transport of 2',3'-dideoxyinosine and adenosine via concentrative Na+ nucleoside transporter CNT2 cloned from rat blood-brain barrier. Li, J.Y., Boado, R.J., Pardridge, W.M. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  26. Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2',3'-dideoxyinosine. Désormeaux, A., Harvie, P., Perron, S., Makabi-Panzu, B., Beauchamp, D., Tremblay, M., Poulin, L., Bergeron, M.G. AIDS (1994) [Pubmed]
  27. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Hartman, N.R., Ahluwalia, G.S., Cooney, D.A., Mitsuya, H., Kageyama, S., Fridland, A., Broder, S., Johns, D.G. Mol. Pharmacol. (1991) [Pubmed]
  28. Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats. Wientjes, M.G., Au, J.L. Antimicrob. Agents Chemother. (1992) [Pubmed]
  29. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Zhang, D., Caliendo, A.M., Eron, J.J., DeVore, K.M., Kaplan, J.C., Hirsch, M.S., D'Aquila, R.T. Antimicrob. Agents Chemother. (1994) [Pubmed]
  30. Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Ray, A.S., Olson, L., Fridland, A. Antimicrob. Agents Chemother. (2004) [Pubmed]
  31. Induction of the SOS response in Escherichia coli by azidothymidine and dideoxynucleosides. Mamber, S.W., Brookshire, K.W., Forenza, S. Antimicrob. Agents Chemother. (1990) [Pubmed]
  32. Expression of deoxynucleotide carrier is not associated with the mitochondrial DNA depletion caused by anti-HIV dideoxynucleoside analogs and mitochondrial dNTP uptake. Lam, W., Chen, C., Ruan, S., Leung, C.H., Cheng, Y.C. Mol. Pharmacol. (2005) [Pubmed]
  33. In vivo and in vitro effects of the azidothymidine analog dideoxyinosine on the exocrine pancreas of the rat. Grady, T., Saluja, A.K., Steer, M.L., Lerch, M.M., Modlin, I.M., Powers, R.E. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  34. A pilot study of 2',3'-dideoxyinosine for the treatment of chronic hepatitis B. Fried, M.W., Korenman, J.C., Di Bisceglie, A.M., Park, Y., Waggoner, J.G., Mitsuya, H., Hartman, N.R., Yarchoan, R., Broder, S., Hoofnagle, J.H. Hepatology (1992) [Pubmed]
  35. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Knupp, C.A., Shyu, W.C., Dolin, R., Valentine, F.T., McLaren, C., Martin, R.R., Pittman, K.A., Barbhaiya, R.H. Clin. Pharmacol. Ther. (1991) [Pubmed]
  36. Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Hartman, N.R., Yarchoan, R., Pluda, J.M., Thomas, R.V., Wyvill, K.M., Flora, K.P., Broder, S., Johns, D.G. Clin. Pharmacol. Ther. (1991) [Pubmed]
  37. Pharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs. Kaul, S., Knupp, C.A., Dandekar, K.A., Pittman, K.A., Barbhaiya, R.H. Antimicrob. Agents Chemother. (1991) [Pubmed]
  38. Uptake kinetics of 2',3'-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies. Anderson, B.D., Hoesterey, B.L., Baker, D.C., Galinsky, R.E. J. Pharmacol. Exp. Ther. (1990) [Pubmed]
WikiGenes - Universities